Long term oncological outcome of thymoma and thymic carcinoma – An analysis of 235 cases from a single institution

Yen Chiang Tseng, Yen Han Tseng, Hua Lin Kao, Chih Cheng Hsieh, Teh Ying Chou, Yih Gang Goan, Wen Hu Hsu, Han Shui Hsu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and objectives: Thymoma has a variable long-term oncological outcome after surgical resection. Survival and tumor recurrence were analyzed to determine the predisposing factors for tumor recurrence. Methods: A total of 235 patients who underwent surgery for thymoma or thymic carcinoma from December 1997 to March 2013 were analyzed using Masaoka staging system and World Health Organization (WHO) histological classification. Surgical intervention included extended thymothymectomy via median sternotomy and thymomectomy via thoracotomy/ video-assisted thoracoscopic surgery (VATS). Results: The median duration of follow-up was 105 months (12–198 months). Among these 235 patients, recurrence was observed in 25 patients (10.7%). according to Masaoka stage I, IIA, IIB, III, IVA, IVB, recurrence rates were 1/65(1.5%), 8/106(7.5%), 1/32(3.1%), 6/20 (30.0%), 8/10(80.0%), 1/1(100.0%), respectively. Disease or treatment-related mortality was observed in 13 patients. Overall survival rate was 94.4%. After univariate analysis, predisposing factors for tumor recurrence included Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status. Conclusions: Due to the indolent behavior of thymoma, tumor recurrence appears to be a better assessment of oncological outcome rather than survival. Factors associated with tumor recurrence include Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status.

Original languageEnglish
Article numbere0179527
JournalPLoS One
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 1 2017
Externally publishedYes

Fingerprint

thymoma
Thymoma
carcinoma
Tumors
Recurrence
neoplasms
World Health Organization
Neoplasms
Health
Causality
Surgery
adjuvants
thoracoscopy
Video-Assisted Thoracic Surgery
therapeutics
Sternotomy
Survival
resection
Factor analysis
Thoracotomy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Long term oncological outcome of thymoma and thymic carcinoma – An analysis of 235 cases from a single institution. / Tseng, Yen Chiang; Tseng, Yen Han; Kao, Hua Lin; Hsieh, Chih Cheng; Chou, Teh Ying; Goan, Yih Gang; Hsu, Wen Hu; Hsu, Han Shui.

In: PLoS One, Vol. 12, No. 6, e0179527, 01.06.2017.

Research output: Contribution to journalArticle

Tseng, Yen Chiang ; Tseng, Yen Han ; Kao, Hua Lin ; Hsieh, Chih Cheng ; Chou, Teh Ying ; Goan, Yih Gang ; Hsu, Wen Hu ; Hsu, Han Shui. / Long term oncological outcome of thymoma and thymic carcinoma – An analysis of 235 cases from a single institution. In: PLoS One. 2017 ; Vol. 12, No. 6.
@article{3053d58d74424ca28dd8e92df7419d49,
title = "Long term oncological outcome of thymoma and thymic carcinoma – An analysis of 235 cases from a single institution",
abstract = "Background and objectives: Thymoma has a variable long-term oncological outcome after surgical resection. Survival and tumor recurrence were analyzed to determine the predisposing factors for tumor recurrence. Methods: A total of 235 patients who underwent surgery for thymoma or thymic carcinoma from December 1997 to March 2013 were analyzed using Masaoka staging system and World Health Organization (WHO) histological classification. Surgical intervention included extended thymothymectomy via median sternotomy and thymomectomy via thoracotomy/ video-assisted thoracoscopic surgery (VATS). Results: The median duration of follow-up was 105 months (12–198 months). Among these 235 patients, recurrence was observed in 25 patients (10.7{\%}). according to Masaoka stage I, IIA, IIB, III, IVA, IVB, recurrence rates were 1/65(1.5{\%}), 8/106(7.5{\%}), 1/32(3.1{\%}), 6/20 (30.0{\%}), 8/10(80.0{\%}), 1/1(100.0{\%}), respectively. Disease or treatment-related mortality was observed in 13 patients. Overall survival rate was 94.4{\%}. After univariate analysis, predisposing factors for tumor recurrence included Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status. Conclusions: Due to the indolent behavior of thymoma, tumor recurrence appears to be a better assessment of oncological outcome rather than survival. Factors associated with tumor recurrence include Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status.",
author = "Tseng, {Yen Chiang} and Tseng, {Yen Han} and Kao, {Hua Lin} and Hsieh, {Chih Cheng} and Chou, {Teh Ying} and Goan, {Yih Gang} and Hsu, {Wen Hu} and Hsu, {Han Shui}",
year = "2017",
month = "6",
day = "1",
doi = "10.1371/journal.pone.0179527",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Long term oncological outcome of thymoma and thymic carcinoma – An analysis of 235 cases from a single institution

AU - Tseng, Yen Chiang

AU - Tseng, Yen Han

AU - Kao, Hua Lin

AU - Hsieh, Chih Cheng

AU - Chou, Teh Ying

AU - Goan, Yih Gang

AU - Hsu, Wen Hu

AU - Hsu, Han Shui

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background and objectives: Thymoma has a variable long-term oncological outcome after surgical resection. Survival and tumor recurrence were analyzed to determine the predisposing factors for tumor recurrence. Methods: A total of 235 patients who underwent surgery for thymoma or thymic carcinoma from December 1997 to March 2013 were analyzed using Masaoka staging system and World Health Organization (WHO) histological classification. Surgical intervention included extended thymothymectomy via median sternotomy and thymomectomy via thoracotomy/ video-assisted thoracoscopic surgery (VATS). Results: The median duration of follow-up was 105 months (12–198 months). Among these 235 patients, recurrence was observed in 25 patients (10.7%). according to Masaoka stage I, IIA, IIB, III, IVA, IVB, recurrence rates were 1/65(1.5%), 8/106(7.5%), 1/32(3.1%), 6/20 (30.0%), 8/10(80.0%), 1/1(100.0%), respectively. Disease or treatment-related mortality was observed in 13 patients. Overall survival rate was 94.4%. After univariate analysis, predisposing factors for tumor recurrence included Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status. Conclusions: Due to the indolent behavior of thymoma, tumor recurrence appears to be a better assessment of oncological outcome rather than survival. Factors associated with tumor recurrence include Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status.

AB - Background and objectives: Thymoma has a variable long-term oncological outcome after surgical resection. Survival and tumor recurrence were analyzed to determine the predisposing factors for tumor recurrence. Methods: A total of 235 patients who underwent surgery for thymoma or thymic carcinoma from December 1997 to March 2013 were analyzed using Masaoka staging system and World Health Organization (WHO) histological classification. Surgical intervention included extended thymothymectomy via median sternotomy and thymomectomy via thoracotomy/ video-assisted thoracoscopic surgery (VATS). Results: The median duration of follow-up was 105 months (12–198 months). Among these 235 patients, recurrence was observed in 25 patients (10.7%). according to Masaoka stage I, IIA, IIB, III, IVA, IVB, recurrence rates were 1/65(1.5%), 8/106(7.5%), 1/32(3.1%), 6/20 (30.0%), 8/10(80.0%), 1/1(100.0%), respectively. Disease or treatment-related mortality was observed in 13 patients. Overall survival rate was 94.4%. After univariate analysis, predisposing factors for tumor recurrence included Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status. Conclusions: Due to the indolent behavior of thymoma, tumor recurrence appears to be a better assessment of oncological outcome rather than survival. Factors associated with tumor recurrence include Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status.

UR - http://www.scopus.com/inward/record.url?scp=85021118017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021118017&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0179527

DO - 10.1371/journal.pone.0179527

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e0179527

ER -